Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis | MicrobiomeTrials← Back to trialsNCT07726888
Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis
RecruitingOBSERVATIONAL
Trial Details
Start: 2026-07-31Est. Completion: 2028-12-31
Enrollment target: 97 participants Locations- The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
Other microbiome trials you might be interested in
Inflammatory Bowel Diseases (IBD)Crohn DiseaseColitis, Ulcerative
Difficult-to-treat inflammatory bowel disease (DTT-IBD) represents a heterogeneous group of patients with treatment-refr…
Multiple LocationsEst. completion Oct 31, 2032
Inflammatory Bowel Disease
This study evaluates oral Lactobacillus reuteri as an adjunct therapy for 2 months. Endoscopic assessments will be perfo…
Suqian, ChinaCompleted Mar 30, 2026
Recruiting
Recurrent C. Difficile (rCDI)Ulcerative Colitis (UC)Metabolic Syndrome (MetS)
The gut microbiota plays a key role in immunity and metabolism and contributes to diseases such as recurrent C. difficil…
Rome, ItalyEst. completion Jan 19, 2029